Skip to main content
Premium Trial:

Request an Annual Quote

Glaxo Ownership in Affy Drops to Below 9 Percent

NEW YORK, June 4 - GlaxoSmithKline has sold a major portion of its stake in Affymetrix, shrinking its ownership in the biochip company from 13 percent to 8.7 percent, filings with the Securities and Exchange Commission show.


On May 15, 16, and 17, the pharmaceutical giant sold 3 million shares of San Francisco-based Affy at $25 per share for a total windfall of approximately $75 million, according to an Affy spokesman.


The two companies have a relationship that dates back to 1995. In addition to the substantial stake in the company, Glaxo is also a major customer for Affymetrix microarray systems.


Shareholders shrugged off the sale. Affy's share price hovered in the mid-$20s for most of May.


GlaxoSmithKline, the biggest drug company in Europe, is still the largest single shareholder in Affymetrix.


The Affy spokesperson, Doug Farrell, said Affy "anticipated" the divestiture, which he said is the latest in a steady and "predictable" sell-off by Glaxo begun 3-4 years ago. In the mid-1990s, Glaxo owned around 60 percent of Affy, according to Farrell. That number fell to 31 percent by the end of 1999.

The Scan

Harvard Team Report One-Time Base Editing Treatment for Motor Neuron Disease in Mice

A base-editing approach restored SMN levels and improved motor function in a mouse model of spinal muscular atrophy, a new Science paper reports.

International Team Examines History of North American Horses

Genetic and other analyses presented in Science find that horses spread to the northern Rockies and Great Plains by the first half of the 17th century.

New Study Examines Genetic Dominance Within UK Biobank

Researchers analyze instances of genetic dominance within UK Biobank data, as they report in Science.

Cell Signaling Pathway Identified as Metastasis Suppressor

A new study in Nature homes in on the STING pathway as a suppressor of metastasis in a mouse model of lung cancer.